Systemic Therapies for Psoriasis: An Evidence-Based Update

Sandoval, Laura F.; Pierce, A.; Feldman, Steven R.

doi:10.1007/s40257-014-0064-x

Cited by 23 publications

(27 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Reported side effects were mild. The 7 Krupashankar et al, 11 Laws and Young, 12 Gooderham, 13 and Patel et al …”

Section: A3 Adenosine Receptor Agonistsmentioning

confidence: 99%

“…7,[36][37][38][39][40][41] This signal transduction in Th17 cells occurs through JAK. Activated Th17 cells produce IL-17A, IL-17F, IL-22, and TNF-α.…”

Section: Th17 Pathway In Psoriasismentioning

confidence: 99%

“…Systemic therapies are recommended in patients when adequate control of disease cannot be accomplished with topical agents. [6][7][8] While measures of disease severity, such as body surface area, are helpful in determining appropriate treatment regimes, the patient's perception of disease burden should determine whether systemic medications might be considered. 7,9,10 Although individualized treatment based on patients' needs is emphasized for the treatment of skin psoriasis, in psoriatic arthritis, prevention of joint destruction and disability should be considered and discussed with the patient.…”

Section: Introductionmentioning

confidence: 99%

“…Currently, the main emphasis of research is on biologics, with newer agents targeting interleukin (IL)-17, one of the key cytokines in the pathogenesis of psoriasis, and on new oral agents in development. 7 As the treatment options for psoriasis expand, with new oral and injectable agents in development, physicians need to have a knowledge of the pharmacodynamics, efficacy, and adverse effects of emerging medications. This paper reviews the recent studies and literature on new medications used for psoriasis.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Emerging treatment options for psoriasis

Taheri¹,

Sandoval²,

Tuchayi³

et al. 2014

PTT

View full text Add to dashboard Cite

Abstract:The treatment of psoriasis has evolved over the years, with the recent focus largely on the use of biologics and anti-interleukin-17 agents. With treatment options expanding, practitioners and patients may find control of psoriasis more convenient and safer to achieve. In this article, we review the literature on emerging medications for the treatment of psoriasis. Although some of the new medications under development, such as the anti-interleukin-17 agents, are being shown to be very efficacious in the treatment of psoriasis in premarketing trials, more information regarding their long-term use is needed to demonstrate their superiority over available modalities.

show abstract

“…Reported side effects were mild. The 7 Krupashankar et al, 11 Laws and Young, 12 Gooderham, 13 and Patel et al …”

Section: A3 Adenosine Receptor Agonistsmentioning

confidence: 99%

“…7,[36][37][38][39][40][41] This signal transduction in Th17 cells occurs through JAK. Activated Th17 cells produce IL-17A, IL-17F, IL-22, and TNF-α.…”

Section: Th17 Pathway In Psoriasismentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Emerging treatment options for psoriasis

Taheri¹,

Sandoval²,

Tuchayi³

et al. 2014

PTT

View full text Add to dashboard Cite

show abstract

“…The following topics are discussed in this issue: atopic dermatitis [3], systemic therapies for psoriasis [4], mucosal lichen planus [5], basal cell carcinoma [6], androgenetic alopecia [7], hirsutism [8], diabetic foot ulcer [9], and alopecia areata [10].…”

mentioning

confidence: 99%